Equities

Bioton SA

Bioton SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (PLN)3.51
  • Today's Change0.005 / 0.14%
  • Shares traded20.13k
  • 1 Year change-7.88%
  • Beta--
Data delayed at least 15 minutes, as of Apr 24 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

  • Revenue in PLN (TTM)181.64m
  • Net income in PLN2.28m
  • Incorporated2004
  • Employees358.00
  • Location
    Bioton SAul. Staroscinska 5WARSZAWA 02-516PolandPOL
  • Phone+48 227214000
  • Fax+48 227211333
  • Websitehttps://bioton.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sds Optic SA530.40k-7.39m161.34m----23.01--304.18-1.30-1.300.09281.190.054-5.912.11---75.38---94.39--167.64---1,395.87--4.85--0.00---99.59---85.26------
Genomtec SA19.00k-13.35m165.48m----15.75--8,709.55-1.32-1.320.00180.8570.001424.230.0095---95.96---115.26---12,973.68---70,247.37--4.05-31.750.1413---81.72---126.20------
Poltreg SA1.40m-13.55m237.84m18.00--2.72--170.00-2.91-2.910.30018.770.011251.220.1876---10.82-6.51-12.42-7.35-811.65-391.38-968.62-449.243.87--0.0856--40.04---588.92--214.26--
Molecure SA1.31m-18.31m248.50m111.00--1.58--189.90-1.17-1.170.08479.340.0085--0.281811,788.92-11.942.52-12.472.64-25.7697.54-1,398.8612.84----0.0434---18.85237.24-19.67---24.82--
Mabion SA151.68m41.27m268.94m226.006.522.285.551.772.552.559.387.290.76914.849.12671,146.0020.93-7.1931.17-16.7975.5458.1027.21-14.271.518.350.2331---7.50--77.94--40.86--
Bioceltix SA0.00-12.73m276.67m----19.44-----3.45-3.450.003.450.00170.52-----112.58---140.07----------5.96--0.0071-------102.87------
BIOTON SA181.64m2.28m300.95m358.00132.310.49638.081.660.02650.02652.127.060.22280.949318.41507,363.100.279-1.990.3437-2.4740.1145.331.25-8.610.29331.900.1018---22.10-5.5160.10-38.690.3284--
Synthaverse SA58.61m4.76m313.25m239.0070.882.9927.515.340.06770.06770.83411.600.27321.662.76245,217.602.223.532.554.3260.0055.628.129.590.97054.470.3834--16.3212.66-21.76--111.77--
Captor Therapeutics SA13.20m-70.58m342.70m104.00--5.45--25.96-16.42-16.423.0414.900.1256--3.59126,932.70-67.13---82.96--52.28---534.69------0.0518--44.15---96.65------
Data as of Apr 24 2024. Currency figures normalised to Bioton SA's reporting currency: Polish New Zloty PLN

Institutional shareholders

0.44%Per cent of shares held by top holders
HolderShares% Held
Dimensional Fund Advisors LPas of 31 Jan 2024237.78k0.28%
Polunin Capital Partners Ltd.as of 30 Jun 2023106.49k0.12%
Dimensional Fund Advisors Ltd.as of 30 Nov 202327.24k0.03%
DFA Australia Ltd.as of 31 Dec 20231.68k0.00%
SSgA Funds Management, Inc.as of 04 Apr 2024848.000.00%
More ▼
Data from 31 Dec 2023 - 18 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.